Ben Leach

Articles

Oncology Nursing Expert Previews 37th Annual ONS Congress

May 2nd 2012

With four full days of programming, dozens of exhibitors, satellite symposia, and thousands of members in attendance, trying to fit everything in at the ONS Annual Congress can prove quite challenging.

Pazopanib Receives FDA Approval for Treatment of Soft Tissue Sarcoma

April 27th 2012

The FDA has approved pazopanib for the treatment of patients with advanced soft tissue sarcoma who have previously received chemotherapy.

Emerging Markers Point to Future Strategies in CLL: An Interview With William G. Wierda, MD, PhD

April 27th 2012

William G. Wierda, MD, PhD, discussed the management of chronic lymphocytic leukemia at the 16th Annual International Congress on Hematologic Malignancies.

Landmark Study Redefines Breast Cancer Into 10 Subtypes

April 25th 2012

Researchers have determined that breast cancer can be classified into 10 different subtypes instead of four subtypes as previously thought.

Oncology Nursing Society Elects New President

April 25th 2012

This year's ONS Annual Congress marks the first at which Mary Gullatte, PhD, RN, APRN, BC, AOCN, will serve as the organization's president.

Hypothyroidism Risks With MKIs Examined

April 23rd 2012

A retrospective analysis of the risks of hypothyroidism in patients who received sunitinib and sorafenib is gaining attention in the field of head and neck cancers.

Elotuzumab Responses High in Multiple Myeloma Study

April 12th 2012

Elotuzumab demonstrated notable response rates as combination therapy in a phase II study of patients with relapsed or refractory multiple myeloma.

New Test Provides More Complete Picture of Recurrence Risk for DCIS

April 4th 2012

A new test specifically designed for breast cancer patients with DCIS appears to be a better indicator of recurrence than other assays for more invasive forms of the disease.

Adjuvant Cetuximab Fails to Improve Survival in Colon Cancer

April 3rd 2012

Patients who received cetuximab in combination with a standard adjuvant therapy treatment for colon cancer did not experience improved survival.

Molecular Profiling Helps Determine Use of New Therapeutic Agents in Breast Cancer

March 29th 2012

For locally advanced breast cancer, molecular profiling may be an effective way to determine which patients respond better to certain therapies.

Supreme Court Asks for Reconsideration on BRCA1 and BRCA2 Patents

March 27th 2012

The US Supreme Court has asked an appellate court to reconsider its decision regarding patents held on two genes.

ODAC Endorses Drug for Rare Leukemia

March 21st 2012

ODAC voted 7-4 (2 abstentions) in support of vincristine sulfate liposomes injection to treat patients with Ph-negative ALL.

ODAC Recommends Pazopanib But Not Ridaforolimus for Sarcoma

March 21st 2012

ODAC has recommended the approval of pazopanib but ruled against the agent ridaforolimus to treat sarcoma.

Drug Interactions Significantly Reduce Targeted Therapy Efficacy

March 16th 2012

The DDIs between Co-Rx medications and targeted OAD is associated with a significant decrease in effectiveness and increased toxicity.

PSA Testing Linked to Reduced Mortality

March 15th 2012

PSA testing was shown to significantly reduce mortality among men, but the test had no effect on all-cause mortality.

Oral HPV Infection Affects 7% of the US Population

March 13th 2012

Approximately 7% of Americans are infected with oral human papillomavirus (HPV), and men are 3 times as likely to be infected as women.

Miami Breast Cancer Conference Founder Keeps Focus on Future

March 12th 2012

As the Miami Breast Cancer Conference enters its 29th year, Osman continues to organize the gathering and pack the 4-day meeting with faculty speakers.

Consensus Elusive on Standard for Lowering Testosterone Levels

March 12th 2012

Once injectable agents were proven to lower testosterone levels, they became the preferred treatment among patients and their treatment teams.

Vemurafenib Doubles Median Survival in Metastatic Melanoma Patients

March 5th 2012

Vemurafenib nearly doubles the median OS in more than 50% of patients with BRAF V600-mutated metastatic melanoma.

A Family Tradition: The Personal Story Behind the Miami Breast Cancer Conference

February 28th 2012

The Miami Breast Cancer Conference has become a well-respected and well-attended gathering that specialists make a point of returning to year after year.